All In Biotech

Drug Trial Radar · NCT01304836

A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids

Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids - A Multicenter, Two Arm, Randomized, Open Label Clinical Study

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,166 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,166

Actual

Start

Jan 22, 2011

Primary completion

May 22, 2013

Study completion May 22, 2013

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Feb 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to focus on potential differences in the occurrence of new-onset Diabetes Mellitus (a glucose metabolism disorder) when two different regimens of immunosuppressive treatment are compared.

Conditions

  • Kidney Transplantation

Interventions

  • AdvagrafDrug

    oral

  • Mycophenolate MofetilDrug

    oral

  • SimulectDrug

    IV

  • CorticosteroidsDrug

    IV \& oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diagnosis of new onset Diabetes Mellitus as per ADA criteria at any point up to 24 weeks after kidney transplantationTime frame: up to 6 months

Locations

100 sites in 24 countries. Site status is shown where the registry gives one.

  • Site not named

    Perth, Australia

  • Site not named

    Sydney, Australia

  • Site not named

    Sydney, Australia

  • Site not named

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Cali, Colombia

  • Site not named

    Brno, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Tartu, Estonia

  • Site not named

    Helsinki, Finland

  • Site not named

    Bordeaux, France

  • Site not named

    Cité Nord, France

  • Site not named

    D'Angers, France

  • Site not named

    Le Puytren, France

  • Site not named

    Montpellier, France

  • Site not named

    Nantes, France

  • Site not named

    Nice, France

  • Site not named

    Paris, France

  • Site not named

    Rennes, France

  • Site not named

    Rouen, France

  • Site not named

    Strasbourg, France

  • Site not named

    Suresnes, France

  • Site not named

    Aachen, Germany

  • Site not named

    Bonn, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Halle, Germany

  • Site not named

    Kaiserslautern, Germany

  • Site not named

    Mannheim, Germany

  • Site not named

    München, Germany

  • Site not named

    Regensburg, Germany

  • Site not named

    Rostock, Germany

  • Site not named

    Debrecen, Hungary

  • Site not named

    Szeged, Hungary

  • Site not named

    Ancona, Italy

  • Site not named

    Bologna, Italy

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.